BR112013000907A2 - composição, partícula nanodimensionada para uso em registro de imagem de raios-x e método para tratamento de uma condição ou doença associada ao crescimento indesejável de células em um indivíduo com necessidade dele - Google Patents

composição, partícula nanodimensionada para uso em registro de imagem de raios-x e método para tratamento de uma condição ou doença associada ao crescimento indesejável de células em um indivíduo com necessidade dele

Info

Publication number
BR112013000907A2
BR112013000907A2 BR112013000907A BR112013000907A BR112013000907A2 BR 112013000907 A2 BR112013000907 A2 BR 112013000907A2 BR 112013000907 A BR112013000907 A BR 112013000907A BR 112013000907 A BR112013000907 A BR 112013000907A BR 112013000907 A2 BR112013000907 A2 BR 112013000907A2
Authority
BR
Brazil
Prior art keywords
treating
individual
composition
condition
need
Prior art date
Application number
BR112013000907A
Other languages
English (en)
Portuguese (pt)
Inventor
Albrechtsen Morten
Lars Andresen Thomas
Original Assignee
Univ Denmark Tech Dtu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Denmark Tech Dtu filed Critical Univ Denmark Tech Dtu
Publication of BR112013000907A2 publication Critical patent/BR112013000907A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agents, e.g. microbubbles introduced into the bloodstream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N5/1039—Treatment planning systems using functional images, e.g. PET or MRI
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1064—Monitoring, verifying, controlling systems and methods for adjusting radiation treatment in response to monitoring
    • A61N5/1065—Beam adjustment
    • A61N5/1067—Beam adjustment in real time, i.e. during treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4064—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam
    • A61B6/4092—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam for producing synchrotron radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
    • A61N2005/1061—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an x-ray imaging system having a separate imaging source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
BR112013000907A 2010-07-16 2011-07-15 composição, partícula nanodimensionada para uso em registro de imagem de raios-x e método para tratamento de uma condição ou doença associada ao crescimento indesejável de células em um indivíduo com necessidade dele BR112013000907A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36491710P 2010-07-16 2010-07-16
EP10169862 2010-07-16
PCT/EP2011/062122 WO2012007567A1 (en) 2010-07-16 2011-07-15 Nanoparticle-guided radiotherapy

Publications (1)

Publication Number Publication Date
BR112013000907A2 true BR112013000907A2 (pt) 2017-10-31

Family

ID=43063934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000907A BR112013000907A2 (pt) 2010-07-16 2011-07-15 composição, partícula nanodimensionada para uso em registro de imagem de raios-x e método para tratamento de uma condição ou doença associada ao crescimento indesejável de células em um indivíduo com necessidade dele

Country Status (9)

Country Link
US (1) US20130204121A1 (https=)
EP (1) EP2593186A1 (https=)
JP (1) JP2013532629A (https=)
CN (1) CN103079642A (https=)
AU (1) AU2011278308B2 (https=)
BR (1) BR112013000907A2 (https=)
CA (1) CA2804849A1 (https=)
MX (1) MX2013000501A (https=)
WO (1) WO2012007567A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782603A1 (en) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
US9370490B2 (en) 2012-02-28 2016-06-21 Loma Linda University Methods for the production, modification and use of metallic nanoparticles
WO2013164725A1 (en) 2012-05-02 2013-11-07 Koninklijke Philips N.V. Spectral ct visualization of imageable drug eluting beads
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
RU2703303C2 (ru) * 2013-05-24 2019-10-16 Данмаркс Текниске Университет Состав геля для лучевой терапии под визуальным контролем
FR3018451A1 (fr) * 2014-03-13 2015-09-18 Chromalys Nanoparticules pour leur utilisation dans la detection de tumeurs mobiles
CN103894557B (zh) * 2014-03-19 2016-01-20 丽水市中心医院 磁共振成像下可视的功能化金纳米粒子的制备方法及应用
US10004695B2 (en) 2014-04-16 2018-06-26 Trustees Of Boston University GM3 functionalized nanoparticles
WO2016004222A1 (en) * 2014-07-01 2016-01-07 Georgia Regents University Bio-compatible radiopaque dental fillers for imaging
JP6501191B2 (ja) * 2014-12-02 2019-04-17 シグマテクノロジー有限会社 マイクロ・ナノバブルによる洗浄方法及び洗浄装置
WO2016115140A1 (en) * 2015-01-13 2016-07-21 Boston Scientific Scimed, Inc. Cancer cell membrane depolarization
WO2016137013A1 (ja) * 2015-02-26 2016-09-01 国立大学法人北海道大学 放射線治療用の病変識別マーカーおよび放射線治療用の病変識別マーカーキット
CA3015663A1 (en) * 2016-03-07 2017-09-14 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
KR102162400B1 (ko) * 2016-05-13 2020-10-06 시그마 테크놀로지 유겐가이샤 생체 투여 가능한 수용액 및 그 제조 방법
EP3500311B1 (en) 2016-08-16 2020-05-27 ETH Zurich Transmembrane ph-gradient polymersomes and their use in the scavenging of ammonia and its methylated analogs
US20190201557A1 (en) * 2016-08-25 2019-07-04 National University Corporation Hokkaido University Lesion identification marker utilizing bone cement for use in radiation therapy, and lesion identification marker kit for use in radiation therapy
WO2019028453A1 (en) * 2017-08-04 2019-02-07 The Cleveland Clinic Foundation RADIATION THERAPY WITH TEMPORAL ATTENUATION
DK3668927T3 (da) 2017-09-12 2024-03-25 Eth Zuerich Transmembran ph-gradient polymersom til kvantificering af ammoniak i kropsvæsker
IL265914B (en) * 2019-04-08 2020-11-30 Convergent R N R Ltd System and method for optimization of radiotherapy treatments
FR3099052B1 (fr) * 2019-07-23 2022-03-25 Univ Franche Comte Structures particulaires à base de nanoparticules d’or, leurs procédés de préparation et leurs utilisations dans le traitement des tumeurs solides
US10929981B1 (en) * 2019-08-21 2021-02-23 Ping An Technology (Shenzhen) Co., Ltd. Gross tumor volume segmentation method and computer device
US12082956B2 (en) * 2019-09-09 2024-09-10 Universidad De La Frontera Integral systems of orthovoltage sources that induce ionizing radiation
CN111467174B (zh) * 2019-12-20 2023-02-17 联影(常州)医疗科技有限公司 一种头部固定装置、血管减影造影系统及透射方法
IT202000001048A1 (it) 2020-01-21 2021-07-21 Univ Degli Studi Padova Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici.
IT202100001049A1 (it) 2021-01-21 2022-07-21 Univ Degli Studi Padova Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818199B1 (en) * 1994-07-29 2004-11-16 James F. Hainfeld Media and methods for enhanced medical imaging
US6645464B1 (en) * 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
JP4282302B2 (ja) * 2001-10-25 2009-06-17 株式会社東芝 Ｘ線ｃｔ装置
WO2003075961A2 (en) * 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging
WO2004017814A2 (en) 2002-08-23 2004-03-04 The Board Of Regents Of University Of Texas System Novel method and composition of identifying inflammation by cat scan
GB2395882B (en) * 2002-11-28 2006-06-14 Elekta Ab Radiotherapy apparatus and operating method
JP4247533B2 (ja) * 2003-09-03 2009-04-02 国立大学法人東京工業大学 呼吸同期装置
WO2005046733A1 (en) * 2003-11-17 2005-05-26 Philips Intellectual Property & Standards Gmbh Contrast agent for medical imaging techniques and usage thereof
US20070031337A1 (en) * 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
WO2006084382A1 (en) 2005-02-11 2006-08-17 University Health Network Compositions and methods for multimodal imaging
DE102005018330B4 (de) * 2005-04-20 2007-04-19 Siemens Ag System zur Erzeugung von CT-Bilddatensätzen und zur Bestrahlung eines Tumor-Patienten
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
WO2007129311A2 (en) 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
KR100810679B1 (ko) * 2006-05-09 2008-03-07 원광대학교산학협력단 금 나노입자를 이용한 엑스-선 조영제 및 이의 제조방법
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US20080213189A1 (en) * 2006-10-17 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Multifunctional metal-graphite nanocrystals
WO2008096279A1 (en) * 2007-02-07 2008-08-14 Spago Imaging Ab Compositions containing metal oxide particles and their uses
US20090088625A1 (en) * 2007-10-01 2009-04-02 Kenneth Oosting Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery
CN101868180A (zh) * 2007-10-09 2010-10-20 圣路易斯华盛顿州立大学 成像粒子
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
WO2009155431A1 (en) * 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
US8784800B2 (en) * 2009-03-09 2014-07-22 Medtronic, Inc. Method of delivering cell therapy to a target site
DK3223013T3 (en) * 2009-07-02 2019-04-15 Sloan Kettering Inst Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES

Also Published As

Publication number Publication date
AU2011278308A1 (en) 2013-01-31
CN103079642A (zh) 2013-05-01
JP2013532629A (ja) 2013-08-19
AU2011278308B2 (en) 2014-09-04
EP2593186A1 (en) 2013-05-22
US20130204121A1 (en) 2013-08-08
WO2012007567A1 (en) 2012-01-19
CA2804849A1 (en) 2012-01-19
MX2013000501A (es) 2013-06-05

Similar Documents

Publication Publication Date Title
BR112013000907A2 (pt) composição, partícula nanodimensionada para uso em registro de imagem de raios-x e método para tratamento de uma condição ou doença associada ao crescimento indesejável de células em um indivíduo com necessidade dele
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0812561A2 (pt) Formulação liofilizada estável preparada, formulação reconstituída estável, método para preparar formulação reconstituída estável e para tratar indivíduo
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI1011413A2 (pt) sistema, método e marcador luminescente para geração de imagem luminescente difusa melhorada ou tomografia em meio de dispersão
ZA201305498B (en) Methods and compositions suitable for managing blood glucose in animals
EP2642924A4 (en) Computed tomography and tomosynthesis system
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
BR112013009483A2 (pt) "estrutura substancialmente desprovida de celulose para utilização em um artigo absorvente, artigo absorvente e método de fabricação de uma estrutura abosrvente"
BRPI0821859A2 (pt) Composição para cuidado oral, uso de um aminoácido básico, em forma livre ou de sal, e, método para aumentar a distribuição de um agente antibacteriano em uma composição para cuidado oral
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0915986A2 (pt) composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
FI20080147L (fi) Maksillofasiaalisen alueen röntgen-tietokonetomografiakuvan kuvantamismenetelmä, röntgen-tietokonetomografialaite ja röntgenkuvan kuvantamislaite
EP2561340A4 (en) Method and system for use in performing security screening
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
PL2468319T3 (pl) Nowy nanoprodukt przydatny w zabiegach profilaktycznych, diagnostycznych oraz leczniczych w medycynie ludzkiej i w weterynarii
AP2013006813A0 (en) Pharmaceutical composition, methods for treating and uses thereof
BRPI0910963A2 (pt) composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
GB201305198D0 (en) Kits, components and methods for tissue reconstruction
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/364,917 DE 16/07/2010 REIVINDICADA NO PCT/EP2011/062122, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("TECHNICAL UNIVERSITY OF DENMARK") SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO FOI APRESENTADO DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPI-PR 179/2017.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.